Hemovent expands Series A
Hemovent said today it received an undisclosed amount of funding as part of an oversubscribed Series A expansion round. The funds came from all existing investors, the Aachen, Germany-based company said, as well as newly invested 1st Capital Partner. Hemovent said that the funding comes shortly after it completed the 1st series of in vivo trials of its artificial lung technology platform which it is developing for a range of indications including extracorporeal CO2 removal and extracorporeal life support. “The fact that all Hemovent investors participated in this new round, and that 1st Capital Partner is an experienced life sciences investment firm known for investing sizable funds in both early-stage and follow-on rounds, bears strong testimony to the opportunity ahead of us as well as the efficient progress we have been able to make to date. Our investors understand Hemovent’s platform is positioned to disrupt a billion-dollar market. In vivo trials have already validated our platform’s superior blood-handling behavior and efficiency parameters compared to standard ECMO. We expect when Hemovent is available by mid-next year it will immediately drive ECMO usage not only for ECLS but also as an effective therapy for respiratory failure indications including ECCO2R protocols,” CEO Christof Lenz said in a prepared statement. Last February, Hemovent said it raised $6m in a Series A round to support its portable extra corporeal membrane oxygenat...
Harvard researchers have developed an artificial intelligence (AI) algorithm...Read more on AuntMinnie.comRelated Reading: AI malware deceives radiologists with fake tumors on CT AI reliably characterizes pulmonary nodules on CT AI spots lung nodules on CT, with low false-positive rate New AI algorithm identifies small lung tumors on CT scans NIH issues huge database of CT scans for AI testing
Researchers from Saudi Arabia have created 3D-printed models based on the CT...Read more on AuntMinnie.comRelated Reading: 3D printing reduces liver transplant costs, surgery time 3D printing yields custom-fit glasses for kids 3D printing helps separate rare case of conjoined twins 3D printing gives pediatric heart surgery a boost 3D-printed lungs improve patient understanding of surgery
Fight Aging! provides a weekly digest of news and commentary for thousands of subscribers interested in the latest longevity science: progress towards the medical control of aging in order to prevent age-related frailty, suffering, and disease, as well as improvements in the present understanding of what works and what doesn't work when it comes to extending healthy life. Expect to see summaries of recent advances in medical research, news from the scientific community, advocacy and fundraising initiatives to help speed work on the repair and reversal of aging, links to online resources, and much more. This content is...
ConclusionsBTT ECMO can be performed as a bridge to LTx without significantly increasing patient mortality in high-volume centers. Patients undergoing BTT ECMO at LTx centers that perform more than 35 LTx annually have equivalent mortality to those who do not require ECMO prior to transplantation.Graphical abstract
Publication date: May 2019Source: American Journal of Kidney Diseases, Volume 73, Issue 5Author(s):
Authors: Shigemura N PMID: 30997234 [PubMed]
Publication date: Available online 18 April 2019Source: Journal of Sport and Health ScienceAuthor(s): Xin Luan, Xiangyang Tian, Haixin Zhang, Rui Huang, Na Li, Peijie Chen, Ru WangAbstractA growing understanding of the benefits of exercise over the past few decades has prompted researchers to take an interest in the possibilities of exercise therapy. Because each sport has its own set of characteristics and physiological complications that tend to appear during exercise training, the effects and underlying mechanisms of exercise remain unclear. Thus, the first step in probing exercise effects on different diseases is the s...
The new heart allocation system in the United States prioritizes patients supported by temporary mechanical circulatory support devices (TMCS) over those with uncomplicated durable continuous-flow left ventricular assist devices (CF-LVAD), which may increase the number of patients bridged to transplant with TMCS. Limited data are available in guiding post-transplant outcomes with various TMCS devices. We sought to describe post-transplant outcome and identify clinical variables associated with post-transplant outcome in patients bridged to transplant with TMCS.
We describe a novel approach for bilateral lung transplantation as off-pump technique via median sternotomy which has the potential to combine the advantages of median sternotomy with less postoperative pain and better chest wall function and off-pump technique with reduced risk of primary graft dysfunction and bleeding complications.
(Reuters Health) - In many parts of the world there are not enough radiation oncologists to design and deliver radiation treatments for lung cancer patients, but that gap could one day be filled with the help of artificial intelligence, researchers suggest in a new study.